An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revance Therapeutics will release its Q4 and full year 2021 financial results on February 28, 2022 after market close. A conference call and live webcast will occur at 4:30 p.m. ET to discuss results and provide a business update. Revance is focused on innovative aesthetic and therapeutic products with a strong pipeline, including DaxibotulinumtoxinA, currently seeking U.S. regulatory approval for glabellar lines and cervical dystonia. They also hold exclusive U.S. rights to the RHA® Collection of dermal fillers.
Positive
Completion of Phase 3 clinical programs for DaxibotulinumtoxinA for Injection.
Pursuing U.S. regulatory approval for DaxibotulinumtoxinA in glabellar lines.
Exclusive U.S. distribution rights to RHA® Collection of FDA-approved dermal fillers.
Negative
None.
Conference Call Scheduled for Monday, February 28, 2022 at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year 2021 financial results on Monday, February 28, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.
Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 8372338; or from the webcast link in the investor relations section of the company's website at: www.revance.com.
A replay of the call will be available beginning February 28, 2022 at 4:30 p.m. PT / 7:30 p.m. ET to March 1, 2022 at 4:30 p.m. PT / 7:30 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 8372338. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance Therapeutics, Inc.
Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.
When will Revance Therapeutics announce its Q4 2021 earnings?
Revance Therapeutics will announce its Q4 2021 earnings on February 28, 2022, after market close.
What time is the Revance Therapeutics conference call scheduled?
The conference call is scheduled for 4:30 p.m. ET on February 28, 2022.
What product is Revance pursuing U.S. regulatory approval for?
Revance is pursuing U.S. regulatory approval for DaxibotulinumtoxinA for Injection in glabellar lines.
What are the key highlights of Revance's pipeline?
Key highlights include DaxibotulinumtoxinA for cervical dystonia and adult upper limb spasticity, alongside exclusive rights to the RHA® dermal fillers.
